361P Innate immune dysregulation in bladder cancer: Altered monocyte and NK cell within the tumor microenvironment

Bladder cancer (BC) is a heterogeneous malignancy classified as non-muscle-invasive (NMIBC) or muscle-invasive (MIBC), with the latter displaying high recurrence and poor response to systemic therapies. Current treatments for MIBC include radical cystectomy and immunotherapy, but their efficacy is limited by immune resistance mechanisms within the tumor microenvironment (TME). The TME contributes to immune evasion and therapeutic failure. Recent evidence suggests a critical role for innate immune populations, including monocytes/macrophages and NK cells, in shaping tumor immune surveillance and therapeutic outcomes.